{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:43:26Z","timestamp":1768567406149,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ymthe.2021.11.012","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T15:55:27Z","timestamp":1637337327000},"page":"1288-1299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model"],"prefix":"10.1016","volume":"30","author":[{"given":"Margherita","family":"Bersani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Rizzuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pagliari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Garbellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Saccomanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong M.","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Nizzardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.11.012_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2021.11.012_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.11.012_bib3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.11.012_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1389202919666180101154916","article-title":"Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates","volume":"19","author":"Maretina","year":"2018","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.ymthe.2021.11.012_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1060028018789956","article-title":"Nusinersen: a treatment for spinal muscular atrophy","volume":"53","author":"Claborn","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ymthe.2021.11.012_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy\u2014\u2014new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2021.11.012_bib7","first-page":"183","article-title":"Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients","volume":"266","author":"Wurster","year":"2019","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.012_bib9","first-page":"CD006282","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2021.11.012_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754501","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","author":"Parente","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ymthe.2021.11.012_bib11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ymthe.2021.11.012_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fneur.2020.00045","article-title":"The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs","volume":"11","author":"Hensel","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib13","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.11.012_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","article-title":"Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy \u03947 mouse model phenotype","volume":"36","author":"Nizzardo","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425247.5.1.105","article-title":"Cell-penetrating peptides for drug delivery across membrane barriers","volume":"5","author":"Foged","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2021.11.012_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.addr.2007.09.002","article-title":"Cell penetrating peptide conjugates of steric block oligonucleotides","volume":"60","author":"Lebleu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2021.11.012_bib18","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2021.11.012_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2021.11.012_bib20","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ymthe.2021.11.012_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy","volume":"27","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib22","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.11.012_bib23","doi-asserted-by":"crossref","first-page":"e82654","DOI":"10.1371\/journal.pone.0082654","article-title":"Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice","volume":"8","author":"d'Errico","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.ymthe.2021.11.012_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.11.012_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.11.012_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1570159X11311020006","article-title":"Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system","volume":"11","author":"Zou","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fneur.2020.00108","article-title":"Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action","volume":"11","author":"Meloni","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib28","doi-asserted-by":"crossref","first-page":"e17161","DOI":"10.7554\/eLife.17161","article-title":"Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of Dapk1","volume":"6","author":"McQueen","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ymthe.2021.11.012_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15216540500494508","article-title":"Properties of cell penetrating peptides (CPPs)","volume":"58","author":"Kerkis","year":"2006","journal-title":"IUBMB life"},{"key":"10.1016\/j.ymthe.2021.11.012_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2006.09.011","article-title":"Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents","volume":"116","author":"Abes","year":"2006","journal-title":"J.\u00a0Control Release: Official J. Control Release Soc."},{"key":"10.1016\/j.ymthe.2021.11.012_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.mt.6300245","article-title":"Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse","volume":"15","author":"Fletcher","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib32","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.1073\/pnas.0805676105","article-title":"Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer","volume":"105","author":"Wu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ymthe.2021.11.012_bib33","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2021.11.012_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnana.2016.00006","article-title":"Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy","volume":"10","author":"Boido","year":"2016","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2021.11.012_bib36","doi-asserted-by":"crossref","first-page":"19348","DOI":"10.1073\/pnas.1319280110","article-title":"Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ymthe.2021.11.012_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnmol.2019.00059","article-title":"Molecular mechanisms underlying sensory-motor circuit dysfunction in SMA","volume":"12","author":"Shorrock","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2021.11.012_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/WCO.0000000000000368","article-title":"Advances in modeling and treating spinal muscular atrophy","volume":"29","author":"Van Alstyne","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib39","first-page":"342","article-title":"The astrocyte odyssey","volume":"86","author":"Wang","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.11.012_bib40","doi-asserted-by":"crossref","first-page":"104870","DOI":"10.1016\/j.nbd.2020.104870","article-title":"Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease?","volume":"140","author":"Abati","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.11.012_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.nbd.2015.12.014","article-title":"The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.11.012_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00109-003-0499-7","article-title":"Role of insulin-like growth factor I signaling in neurodegenerative diseases","volume":"82","author":"Trejo","year":"2004","journal-title":"J.\u00a0Mol. Med. (Berlin, Germany)"},{"key":"10.1016\/j.ymthe.2021.11.012_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/108729003764097322","article-title":"HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers","volume":"13","author":"Moulton","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.ymthe.2021.11.012_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnmol.2014.00081","article-title":"Intravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile mice","volume":"7","author":"Gombash","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2021.11.012_bib45","first-page":"1","article-title":"The Lowry method for protein quantitation","volume":"1","author":"Waterborg","year":"1984","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.ymthe.2021.11.012_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2007.04.009","article-title":"Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy","volume":"27","author":"Butchbach","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.11.012_bib47","doi-asserted-by":"crossref","first-page":"e0128560","DOI":"10.1371\/journal.pone.0128560","article-title":"Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model","volume":"10","author":"Valsecchi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2021.11.012_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(95)00463-Z","article-title":"Distribution of glial fibrillary acidic protein (GFAP) in the cochlear nucleus of adult and aged rats","volume":"686","author":"Jalenques","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2021.11.012_bib49","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.3390\/ijms21217918","article-title":"Increased skeletal muscle fiber cross-sectional area, muscle phenotype shift, and altered insulin signaling in rat hindlimb muscles in a prenatally androgenized rat model for polycystic ovary syndrome","volume":"21","author":"DeChick","year":"2020","journal-title":"Int. J. Mol. Sci."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621005839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621005839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:44:29Z","timestamp":1716245069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621005839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1525001621005839"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}